Tower Research Capital (TRC)
PMCB icon

Tower Research Capital (TRC)’s PharmaCyte Biotech PMCB Stock Holding History

Tower Research Capital (TRC)’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76K Hold
257
– – ﹤0.01% 4475
2026
Q1 		$3.25K Sell
257
-1
-0.4% -$15 ﹤0.01% 4344
2025
Q4 		$3.55K Sell
258
-34
-12% -$582 ﹤0.01% 4355
2025
Q3 		$5.38K Buy
292
+145
+99% +$2.74K ﹤0.01% 4239
2025
Q2 		$3.04K Sell
147
-34
-19% -$721 ﹤0.01% 4562
2025
Q1 		$4.3K Buy
181
+52
+40% +$1.6K ﹤0.01% 4278
2024
Q4 		$3.84K Sell
129
-22
-15% -$721 ﹤0.01% 4575
2024
Q3 		$5.46K Sell
151
-238
-61% -$8.42K ﹤0.01% 4269
2024
Q2 		$14.5K Buy
389
+219
+129% +$8.96K ﹤0.01% 3947
2024
Q1 		$7.65K Buy
170
+71
+72% +$2.92K ﹤0.01% 4174
2023
Q4 		$4.05K Buy
99
+35
+55% +$1.44K ﹤0.01% 5001
2023
Q3 		$2.56K Buy
+64
New +$3.1K ﹤0.01% 5135
2023
Q2 		– Sell
-27
Closed -$1K – 6290
2023
Q1 		$1K Buy
27
+16
+145% +$894 ﹤0.01% 5594
2022
Q4 		$1K Buy
11
+6
+120% +$326 ﹤0.01% 5649
2022
Q3 		$0 Sell
5
-56
-92% -$2.69K ﹤0.01% 6391
2022
Q2 		$2K Buy
+61
New +$2.53K ﹤0.01% 5584
2022
Q1 		– Sell
-34
Closed -$2K – 6451
2021
Q4 		$2K Sell
34
-338
-91% -$17.7K ﹤0.01% 5651
2021
Q3 		$22K Buy
+372
New +$24.8K ﹤0.01% 3638

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Tower Research Capital (TRC)'s PMCB Position: Q2 2026 in Review

Tower Research Capital (TRC) held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 257 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Tower Research Capital (TRC) first reported a position in PMCB in Q3 2021 and has held it in 18 quarters since. The position peaked at $22K in Q3 2021. 20 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Tower Research Capital (TRC) held 257 shares of PharmaCyte Biotech worth $3.76K as of Q2 2026.
  • Tower Research Capital (TRC) left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4475 holding.
  • Tower Research Capital (TRC) first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s PharmaCyte Biotech position peaked at $22K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.